ICML 2021 | Pirtobrutinib: The next generation of BTK inhibitors
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses using pirtobrutinib in treating chronic lymphocytic leukemia (CLL). Pirtobrutinib differs from other Bruton’s tyrosine kinase (BTK) inhibitors as it binds non-covalently to BTK and has consequently proven to be efficacious in patients with BTK-resistant CLL in clinical trials. Approval of pirtobrutinib will provide more treatment options for patients with CLL and may delay the onset of refractory CLL in patients. This is interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
Transcript (edited for clarity)
This is very interesting and we’ll have a completely new, different aspect in treating CLL. For example, the BTK inhibitor pirtobrutinib is a BTK inhibitor which is binding non-covalently to BTK and therefore still acting in patients having the BTK resistance mutation.
And first data on patients having received prior other BTK inhibitors, shown very good response data and therefore the substance is currently developed in clinical trials and hopefully available in a few, very few years...
This is very interesting and we’ll have a completely new, different aspect in treating CLL. For example, the BTK inhibitor pirtobrutinib is a BTK inhibitor which is binding non-covalently to BTK and therefore still acting in patients having the BTK resistance mutation.
And first data on patients having received prior other BTK inhibitors, shown very good response data and therefore the substance is currently developed in clinical trials and hopefully available in a few, very few years. And then we will, similar as in CML, have also different options of treatment with BTK inhibitors, which act differently.
And this will be a completely new aspect for the treatment of CLL patients because then we could delay the time point where refractoriness is becoming a significant event for patients over survival and we can delay this time point for them.
Read more...
